Literature DB >> 12044538

Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.

Olivier Loréal1, Bruno Turlin, Christelle Pigeon, Annick Moisan, Martine Ropert, Patrick Morice, Yves Gandon, Anne-Marie Jouanolle, Marc Vérin, Robert C Hider, Kunihiro Yoshida, Pierre Brissot.   

Abstract

Aceruloplasminemia is an autosomal recessive disease of iron overload associated with mutation(s) in the ceruloplasmin gene. We report here a new case of aceruloplasminemia in a woman who is a compound heterozygote for two new mutations. Besides this novel genotypic profile, this observation provides new insights on: (i) iron metabolism with normal erythroid repartition, in the absence of serum non-transferrin-bound iron and with an increase of 59Fe plasma clearance; (ii) hepatic abnormalities associated with the presence of iron-free foci; (iii) the therapeutic management of the disease, chronic subcutaneous infusion of deferrioxamine being remarkably effective at reducing hepatic iron overload.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044538     DOI: 10.1016/s0168-8278(02)00042-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  Aceruloplasminemia: a case report.

Authors:  Domenico Di Raimondo; Antonio Pinto; Antonino Tuttolomondo; Paola Fernandez; Clara Camaschella; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2008-04-12       Impact factor: 3.397

Review 2.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 3.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

4.  MR imaging of cerebral cortical involvement in aceruloplasminemia.

Authors:  Marina Grisoli; Alberto Piperno; Luisa Chiapparini; Raffaella Mariani; Mario Savoiardo
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

5.  Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.

Authors:  L Poli; A Alberici; P Buzzi; E Marchina; A Lanari; C Arosio; A Ciccone; F Semeraro; R Gasparotti; A Padovani; Barbara Borroni
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

6.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

7.  Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Authors:  R Mariani; C Arosio; S Pelucchi; M Grisoli; A Piga; P Trombini; A Piperno
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications.

Authors:  Hsi-Huang Tseng; Jan-Gowth Chang; Yaw-Huei Hwang; Kun-Tu Yeh; Yao-Li Chen; Hsin-Su Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-23       Impact factor: 4.553

Review 9.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

10.  T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation.

Authors:  A McNeill; D Birchall; S J Hayflick; A Gregory; J F Schenk; E A Zimmerman; H Shang; H Miyajima; P F Chinnery
Journal:  Neurology       Date:  2008-04-29       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.